A Pathologic Complete Response to Neoadjuvant Chemotherapy and Immunotherapy Followed by Surgery in a Patient with NSCLC.

Xiao Ma,Bin Li,Yuan Li,Liming Lu,Haiquan Chen

DOI: https://doi.org/10.1016/j.jtho.2018.12.025

IF: 20.121

2019-01-01

Journal of Thoracic Oncology

Abstract:Many clinical studies have focused on developing neoadjuvant chemotherapy combined with surgical treatment for advanced lung cancer. The NSCLC Meta-analysis Collaborative Group suggested that the absolute survival improvement of preoperative chemotherapy for resectable NSCLC at 5 years was only 5%.1NSCLC Meta-analysis Collaborative GroupPreoperative chemotherapy for non–small-cell lung cancer: a systematic review and meta-analysis of individual participant data.Lancet. 2014; 383: 1561-1571Abstract Full Text Full Text PDF PubMed Scopus (467) Google Scholar Presently, the optimal treatment strategies for advanced lung cancer are still evolving. In the era of immunotherapy, programmed death 1 pathway blockade in early-stage lung cancer can enhance antitumor effects.2McGranahan N. Furness A.J. Rosenthal R. et al.Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.Science. 2016; 351: 1463-1469Crossref PubMed Scopus (1962) Google Scholar Forde et al.3Forde P.M. Chaft J.E. Smith K.N. et al.Neoadjuvant PD-1 blockade in resectable lung cancer.N Engl J Med. 2018; 379: e14Crossref PubMed Scopus (41) Google Scholar suggested that neoadjuvant nivolumab did not delay surgery, and induced a major pathologic response in 45% of resected tumors. Herein, our current study presents a rare case of advanced lung cancer with a complete pathological response to preoperative chemotherapy plus pembrolizumab (Keytruda, Merck & Co., Kenilworth, New Jersey) and surgery. A 45-year-old Chinese male smoker presented with a history of 2-week productive cough and bloody sputum. Positron-emission tomography/computed tomography (CT) showed a mass in the right hemithorax measuring 60 mm and an enlarged right hilar lymph node (Fig. 1). Bronchoscope biopsy confirmed poorly differentiated adenocarcinoma. Molecular testing of the pathologic specimen was negative for EGFR, ALK, and ROS1 mutations. As such, the patient’s tumor was staged as cT3N2M0 (stage IIIB). He received two cycles of pemetrexed (900mg d1) and cisplatin (45mg d1-3), followed by two cycles of pemetrexed (900mg d1), cisplatin (45mg d1-3) plus Keytruda (100mg d6). After all four cycles of treatment, enhanced CT scan showed that the right upper lobe lesion decreased to 35 mm (Fig. 2). Then, after careful multidisciplinary discussion, the patient underwent right upper lung lobectomy plus radical mediastinal lymph node dissection. Pathologic results revealed inflammatory cell infiltration, multinucleated giant cell reaction, cholesterol crystallization, and calcium salt deposition in the lung tissues; no viable tumor cells remained (Fig. 3). Lymph nodes at levels 2, 7, 8, 10, and 11 tested negative. We performed further flow cytometry on the patient's postoperative pathologic specimens (Table 1). The purity of the tumor cells was very low (6.91%), the expression of immune cells in tumor tissues was less than 1% (0.97%), the expression of programmed death ligand 1 was 27.4%, and the expression of programmed death ligand 2 was 92.3%.Figure 2Right upper lobe mass after four cycles of treatment.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 3(A) Hematoxylin and eosin (HE) stain of tumor bed (original magnification ×100) with no viable tumor cells. (B) HE stain of lymph node (original magnification ×100) with no viable tumor cells.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Table 1Results of Flow Cytometry of Postoperative Pathological SpecimensDetection IndicatorProportionEpCAM+6.91%PDL1/EpCAM+27.40%PDL2/EpCAM+92.30Granulocyte/CD45+33.90pDCs/CD45+26.30PDL1/Granulocyte92.30PDL2/Granulocyte33.80Monocyte0%CD45+0.97%CD3/CD45+88.20%NKT/CD45+3.51%NK/CD45+0.58%CD4/CD45+69.80%DPT/CD45+2.10%DNT/CD45+4.91%CD8/CD45+11.37%Ki67/CD4+2.85%CD40LCD4+1.34%Treg/CD4+11.60%Tfh/CD4+2.51%Ki67/CD8+8.25%CD40L/CD8+1.03%CD4/CD86.14 Open table in a new tab In conclusion, this report showed an NSCLC patient with complete pathological response after comprehensive treatment. Although long-term follow-up is still needed to confirm the rationale of the treatment strategy, no sign of recurrence has been observed during the past 11 months. There is an obvious need for more research and better-defined protocols and expectations for the role of programmed death 1 inhibitors in future treatment algorithms for NSCLC. Download .docx (.6 MB) Help with docx files Supplemental Digital Content